ANNOVIS BIO INC. COMMON STOCK

Annovis Bio Announces Positive Interim Independent Analysis for Statistical Power in Its Alzheimer’s Study

12 Oct 2023 08:02:38 By Nasdaq GlobeNewswire

Annovis Bio Announces First Quarter 2023 Financial Results and Provides Corporate Update

11 May 2023 07:00:01 By Nasdaq GlobeNewswire

Annovis Bio Announces Issuance of U.S. Patent Covering the Use of Lead Drug Candidate, Buntanetap, for Prevention or Treatment of Disease States Due to Metal Dis-Homeostasis in Healthy or Sick Humans

27 Apr 2023 07:00:00 By Nasdaq GlobeNewswire

Annovis Bio, Inc. to present at the Q1 Virtual Investor Summit 

11 Mar 2021 07:05:00 By Nasdaq GlobeNewswire

Annovis Bio to Present at the BIO CEO & Investor Digital Conference

16 Feb 2021 06:45:00 By Nasdaq GlobeNewswire